A potential therapeutic effect of catalpol in Duchenne muscular dystrophy revealed by binding with TAK1

BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive muscle disease caused by the loss of dystrophin, which results in inflammation, fibrosis, and the inhibition of myoblast differentiation in skeletal muscle. Catalpol, an iridoid glycoside, improves skeletal muscle function by enhancing m...

詳細記述

保存先:
書誌詳細
出版年:J Cachexia Sarcopenia Muscle
主要な著者: Xu, Dengqiu, Zhao, Lei, Jiang, Jingwei, Li, Sijia, Sun, Zeren, Huang, Xiaofei, Li, Chunjie, Wang, Tao, Sun, Lixin, Li, Xihua, Jiang, Zhenzhou, Zhang, Luyong
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2020
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7567147/
https://ncbi.nlm.nih.gov/pubmed/32869445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcsm.12581
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料